HHC
GILD icon

Hutchin Hill Capital’s Gilead Sciences GILD Stock Holding History

Hutchin Hill Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-78,216
Closed -$5.31M – 905
2017
Q1 		$5.31M Buy
+78,216
New +$5.5M 0.15% 153
2014
Q4 		– Sell
-39,500
Closed -$4.21M – 603
2014
Q3 		$4.21M Buy
+39,500
New +$3.87M 0.16% 152
2014
Q2 		– Sell
-133,300
Closed -$9.45M – 650
2014
Q1 		$9.45M Buy
133,300
+39,100
+42% +$3.07M 0.49% 45
2013
Q4 		$7.07M Buy
+94,200
New +$6.56M 0.48% 46
2013
Q3 		– Sell
-35,200
Closed -$1.8M – 510
2013
Q2 		$1.8M Buy
+35,200
New +$1.83M 0.19% 83

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hutchin Hill Capital's GILD Position: Q2 2017 in Review

Hutchin Hill Capital sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 78,216 shares — an estimated $5.31M sold.

Hutchin Hill Capital first reported a position in GILD in Q2 2013 and held it in 5 quarters. The position peaked at $9.45M in Q1 2014. 1,519 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

  • Hutchin Hill Capital reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 78,216 Gilead Sciences shares in Q2 2017, an estimated $5.31M.
  • Hutchin Hill Capital first reported a position in Gilead Sciences in Q2 2013 and held it in 5 quarters.
  • Hutchin Hill Capital's Gilead Sciences position peaked at $9.45M in Q1 2014.
  • 1,519 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.